within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BD11_Fesoterodine;

model Fesoterodine
  extends Pharmacolibrary.Drugs.ATC.G.G04BD11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>G04BD11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fesoterodine is an antimuscarinic agent used for the treatment of overactive bladder with symptoms of urinary frequency, urgency, and urge incontinence. It is an approved oral medication active as a prodrug, rapidly converted to its active metabolite 5-hydroxymethyl tolterodine (5-HMT).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of fesoterodine (as its active metabolite 5-HMT) were characterized in healthy adult subjects (male and female, age 18-55) after administration of the recommended 8 mg oral dose in the fasted state.</p><h4>References</h4><ol><li><p>Shin, D, et al., &amp; Yu, KS (2012). Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 50(10) 722–728. DOI:<a href=\"https://doi.org/10.5414/CP201708\">10.5414/CP201708</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22853865/\">https://pubmed.ncbi.nlm.nih.gov/22853865</a></p></li><li><p>Malhotra, B, et al., &amp; Wood, N (2009). Evaluation of drug-drug interactions with fesoterodine. <i>European journal of clinical pharmacology</i> 65(6) 551–560. DOI:<a href=\"https://doi.org/10.1007/s00228-009-0648-1\">10.1007/s00228-009-0648-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19347334/\">https://pubmed.ncbi.nlm.nih.gov/19347334</a></p></li><li><p>Malhotra, BK, et al., &amp; Sachse, R (2009). Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. <i>International journal of clinical pharmacology and therapeutics</i> 47(9) 570–578. DOI:<a href=\"https://doi.org/10.5414/cpp47570\">10.5414/cpp47570</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19761716/\">https://pubmed.ncbi.nlm.nih.gov/19761716</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fesoterodine;
